

# Clinical trials of Drug eluting stent for coronary artery disease in bypass graft lesion

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 drug-eluting stents

Trial	Treatments	Patients	Trials design and methods
<b>DES vs bare-metal stent</b>			
<b>ISAR-CABG , 2011</b> [NCT00611910] n=303/307 follow-up: 12 montsh (35 mo)	Drug-eluting stent (paclitaxel-eluting, sirolimus-eluting, or bioabsorbable polymer sirolimus-eluting stent) versus bare metal stent	patients with Bypass Graft Lesions	Parallel groups open
<b>drug-eluting stents vs bare-metal stent</b>			
<b>ISAR-CABG</b> <i>ongoing</i> [NCT00611910] n=NA follow-up:	DES versus BMS	Bypass Graft Lesions	open
<b>paclitaxel eluting stent vs bare-metal stent</b>			
<b>SOS , 2008</b> [NCT00247208] n=41/39 follow-up: 1.5y median	Paclitaxel-Eluting Stent (Taxus) versus bare metal stent (Express-2)	patients undergoing percutaneous coronary intervention of saphenous vein bypass grafts	Parallel groups open USA, Greece
<b>BASKET-SAVAGE</b> <i>ongoing</i> [NCT00595647] n=NA follow-up:	Taxus versus Libert	percutaneous coronary interventions of saphenous vein grafts	open
<b>sirolimus eluting stent vs bare-metal stent</b>			
<b>RRISC , 2006</b> [NCT00263263] n=38/37 follow-up: 6 months (3 years)	Cypher versus BX-Velocity	Stable or unstable AP, with previous coronary artery bypass surgery and degenerated vein grafts	Parallel groups open Belgium, The netherlands
<b>paclitaxel eluting stent vs medical treatment</b>			
<b>VELETI</b> <i>ongoing</i> [NCT00289835] n=NA follow-up:	TAXUS versus standard medical treatment	Moderate Vein Graft Lesions	

## References

### ISAR-CABG, 2011:

Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schmig A, Kastrati A Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet* 2011 Aug 26; [21872918]

[10.1016/S0140-6736\(11\)61255-5](https://doi.org/10.1016/S0140-6736(11)61255-5)

**ISAR-CABG, 0:**

**SOS, 2008:**

Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. *J Am Coll Cardiol* 2009 Mar 17;53:919-28 [[19281920](#)]

Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. *JACC Cardiovasc Interv* 2011;4:176-82 [[21349456](#)] [10.1016/j.jcin.2010.10.003](https://doi.org/10.1016/j.jcin.2010.10.003)

**BASKET-SAVAGE, 0:**

**RRISC, 2006:**

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. *J Am Coll Cardiol* 2007 Jul 17;50:261-7 [[17631219](#)]

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. *J Am Coll Cardiol* 2006 Dec 19;48:2423-31 [[17174178](#)]

**VELETI, 0:**

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.